Elutia reports 26% year-over-year sales growth of proprietary products and strengthened balance sheet in third quarter 2023 financial results

- anticipate 510(k) filing for transformational drug-eluting biomatrix cangaroorm in fourth quarter silver spring, md., nov. 13, 2023 (globe newswire) -- elutia inc. (nasdaq: elut) (“elutia”), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended september 30, 2023.
ELUT Ratings Summary
ELUT Quant Ranking